Oncology has been an easy area for employers to adopt biosimilars because of the rising costs in the space, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions. Now that multiple adalimumab (Humira) biosimilars are hitting the US market, employers should take a step back to review their current strategy around the drug.
Oncology has been an easy area for employers to adopt biosimilars because of the rising costs in the space, said Margaret Rehayem, vice president, National Alliance of Healthcare Purchaser Coalitions. Now that multiple adalimumab (Humira) biosimilars are hitting the US market, employers should take a step back to review their current strategy around the drug.
Transcript
The oncology space has the most biosimilar approvals and the greatest uptake right now among providers. Are you seeing comfort levels with using biosimilars vary among employers depending on the disease state?
I think there are some employers that are more comfortable depending on disease state. Some just blanket want to be able to have biosimilars on formulary in general. But I think as the market grows here, the familiarity around biosimilars, that conversation becomes easier for employers, there will be more traction across more disease states. Oncology is an easy one, because employers have really over time wanted to get out of the way, not to have any barriers at all around medications and treatments. But the costs are really rising in that space, too. So, they have to balance affordability.
This year, at least 8—and as many as 10—Humira biosimilars are going to hit the US market. Is there a challenge for employers to manage so much competition hitting all at once?
Yes, is the short answer. And I know you don't want me to stop there. I think employers that were in our learning collaborative, that this was what their number 1 issue, as we're moving into 2023: is what can and should they be doing?
There are a number of strategies that we highlight in our playbook for them to take a look at and consider as they're looking at their strategy. But one of them is really going back and asking their PBM [pharmacy benefit manager] what they're currently looking to do with Humira? What is currently their strategy around that? And does that really fit the employer’s needs?
They almost have to step back a little bit and see what their health plan and PBM are looking to do, and then really put in place what's necessary moving forward. This is not going to be something that is a cookie cutter approach. It's not something that we can say, “Employers just do these 3 things, and you'll be okay.” There are no guarantees here. But what we do want to encourage employers to do is lean in rather than lean back on Humira.
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
What We’re Reading: Abortion Privacy Rules; Alzheimer Drug Hurdles; Nursing Home Staffing Overhaul
April 23rd 2024New health privacy rules aim to protect patients and providers in an evolving abortion landscape; some physicians express concerns about efficacy, risks, and entrenched beliefs in treating Alzheimer disease; CMS addresses longstanding staffing deficits in nursing homes.
Read More